Dingdang Health Technology Group Ltd.

Dingdang Health Technology Group Ltd.

HHKEX:9886
0.87
HKD
-0.01
(-1.14%)
1.18BMarket Cap
Mar 31Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.44
0.95
1.66
2.74
5.15
3.63
3.53
3.76
- -
Basic EPS, GAAP
-0.08
-0.21
-0.69
-1.18
-3.37
-0.17
-0.28
-0.04
- -
Free Cash Flow per Basic Share
- -
-0.22
-0.16
-0.24
-0.32
-0.02
-0.03
0.08
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.13
-0.33
-1.01
-1.95
1.63
1.52
1.26
1.27
1.23
Tangible Book Value per Share
-0.15
-0.43
-1.38
-2.29
1.31
1.23
1.14
1.18
1.19
Basic Weighted Avg Shares
1,341
1,341
1,341
1,341
841
1,339
1,323
1,299
1,286
Sales/Revenue/Turnover
585
1,276
2,229
3,679
4,329
4,857
4,669
4,888
- -
Operating Margin (%)
-10.75
-9.1
-6.72
-17.77
-7.36
-5.53
-4.3
-0.79
- -
Depreciation Expense
33
57
75
135
135
140
138
141
- -
Net Income, GAAP
-108
-277
-924
-1,578
-2,833
-226
-376
-49
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-18.4
-21.69
-41.47
-42.9
-65.45
-4.65
-8.06
-1
- -
Working Capital
-133
113
492
1,529
1,558
1,459
1,370
1,199
1,147
LT Debt
45
80
87
96
91
84
98
205
186
Total Equity
-161
-437
-1,305
-2,590
2,199
2,037
1,680
1,675
1,535
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-10.69
-20.36
-2.95
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
63
76
76
LT Borrowings
- -
- -
- -
LT Finance Leases
200
205
186
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,319
1,310
1,241
Market Capitalization
650
1,260
1,020

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
2,354
2,136
2,254
Cash, Cash Equivalents & STI
1,359
1,089
1,129
Accounts Receivable, Net
128
121
164
Inventories
625
648
679
Total Current Liabilities
997
937
1,107
Payables & Accruals
- -
- -
- -
ST Debt
63
76
76
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-22.34%
-0.32%
Free Cash Flow
- -
-78.75%
-377.5%
Net Income, GAAP
- -
7.6%
-86.98%
Sales/Revenue/Turnover
- -
19.15%
4.68%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4,669
2025
- -
- -
4,888
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.28
2025
- -
- -
-0.04
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Wenlong Yang
Full Time Employees
2,232
Sector
Retail trade
Industry
Drugstore chains
Address
Building 1 Beijing BE China
IPO Date
Sep 14, 2022
Website
ddjkjt.com
Business
Dingdang Health Technology Group Ltd. is a digital healthcare service provider headquartered in Beijing, China, founded in 2014. The company operates primarily in the People's Republic of China, offering a comprehensive range of health products and services through both offline retail and online direct sales channels. Its core services include on-demand pharmaceutical retail under a drug express model; online medical consultation covering medication, nutrition, and healthcare advice through its Internet hospitals and an extensive medical team; chronic disease and healthcare management services incorporating medication guidance, prescription renewals, and health portfolio management; and Directly Observed Therapy (DOT) medication adherence services. In recent developments, Dingdang Health has focused on expanding its self-operated smart pharmacies across second-tier and selected third-tier cities in China, leveraging organic growth and acquisitions to broaden geographic and service coverage. The company continues to enhance its product offerings, particularly increasing its variety within prescription drugs, which constitute a significant revenue share. Dingdang Health actively integrates new business areas such as on-demand point-of-care testing for conditions like bone and vascular health, as well as cross-border e-commerce for pharmaceutical and healthcare products. In 2024 and 2025, the company reinforced its corporate governance by establishing nomination committees and implementing traceable quality control systems to support its digital medical and health service innovations. It has also engaged in share repurchase programs, signaling confidence in its strategic direction. Dingdang Health operates within the pharmaceutical and healthcare industry, targeting consumers seeking accessible, affordable, and technologically integrated health solutions across China. It leverages proprietary technology platforms and extensive research and development capabilities. The company is positioning itself as a pioneer in the rapid digital healthcare sector by integrating online-to-offline service models, aiming to build an in-depth ecosystem encompassing treatment, diagnosis, pharmaceutical products, and medical insurance through strategic upstream and downstream cooperation. Overall, Dingdang Health Technology Group Ltd. delivers a diverse portfolio of pharmaceutical products and digital health services, backed by recent operational expansions, product innovations, and strategic ecosystem development aimed at reshaping China's healthcare landscape.